Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF
- 292 Downloads
Lung ultrasound (LUS) can be used to assess pulmonary congestion by imaging B-lines (‘comets’) for patients with acute heart failure (AHF).
Investigate relationship of B-lines, plasma concentrations of B-type natriuretic peptide (BNP), and echocardiographic left ventricular (LV) function measured at admission and discharge and their relationship to prognosis for AHF with preserved (HFpEF) or reduced (HFrEF) LV ejection fraction.
Patients with AHF had the above tests done at admission and discharge. The primary outcome was re-hospitalization for heart failure or death at 6 months.
Of 162 patients enrolled, 95 had HFrEF and 67 had HFpEF, median age was 80 [77–85] years, and 85 (52%) were women. The number of B-lines at admission (median 31 [27–36]) correlated with respiratory rate (r = 0.75; p < 0.001), BNP (r = 0.43; p < 0.001), clinical congestion score (r = 0.25; p = 0.001), and systolic pulmonary artery pressure (r = 0.42; p < 0.001). At discharge, B-lines were also correlated with BNP (r = 0.69; p < 0.001) and congestion score (r = 0.57; p < 0.001). B-line count at discharge predicted outcome (AUC 0.83 [0.77–0.90]; univariate HR 1.12 [1.09–1.16]; p < 0.001; multivariable HR 1.16 [1.11–1.21]; p < 0.001). Results were similar for HFpEF and HFrEF.
LUS appears a useful method to assess severity and monitor the resolution of lung congestion. At hospital admission, B-lines are strongly related to respiratory rate, which may be a key component of the sensation of dyspnea. Measurement of lung congestion at discharge provides prognostic information for patients with either HFpEF or HFrEF.
KeywordsLUS Acute HF HFpEF HFrEF Risk stratification
Acute heart failure
B-type natriuretic peptide
Heart failure with preserved ejection fraction
Heart failure with reduced ejection fraction
Isovolumetric relaxation time
Systolic pulmonary artery pressure
Receiving operating characteristics
AP and GR helped conceive and design the study and interpreted the results AP supervised the research and wrote the first draft of the manuscript. GR provided statistical analysis and revised the manuscript. MB helped acquire data. RN and JGC contributed to data interpretation and revision of the manuscript. All authors gave final approval of the version to be published.
Compliance with ethical standards
Conflict of interest
Dr. Palazzuoli, Ruocco, Beltrami, and Nuti report no relevant conflicts; Prof. J. G. Cleland has received research grants from Amgen, Novartis, and Stealth Biopharmaceuticals.
- 2.Gheorghiade M, Gattis WA, O’Connor CM; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators et al (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291:1963–1971Google Scholar
- 5.Lala A, McNulty SE, Mentz RJ et al (2015) Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from diuretic optimization strategy evaluation in acute decompensated heart failure (DOSE-AHF) and cardiorenal rescue study in acute decompensated heart failure (CARESS-HF). Circ Heart Fail 8:741–748CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Ponikowski P, Voors AA, Anker SD; Authors/Task Force Members; Document Reviewers et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Gheorghiade M, Follath F, Ponikowski P; European Society of Cardiology; European Society of Intensive Care Medicine et al (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 12:423–433CrossRefPubMedGoogle Scholar
- 14.Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16:233–270CrossRefPubMedGoogle Scholar
- 15.Nagueh SF, Smiseth OA, Appleton CP et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 17:1321–1360CrossRefPubMedGoogle Scholar
- 18.Volpicelli G, Elbarbary M, Blaivas M; International Liaison Committee on Lung Ultrasound (ILC-LUS) for International Consensus Conference on Lung Ultrasound (ICC-LUS) et al (2012) International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med 38:577–591CrossRefPubMedGoogle Scholar
- 26.Gaggin HK, Truong QA, Rehman SU et al (2013) Characterization and prediction of natriuretic peptide “nonresponse” during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail 19:135–142CrossRefPubMedGoogle Scholar
- 28.Cleland JG, Teerlink JR, Davison BA; VERITAS Investigators et al (2017) Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). Eur J Heart Fail 19:739–747CrossRefPubMedGoogle Scholar
- 30.Mebazaa A, Yilmaz MB, Levy P et al (2015) Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 17:544–558CrossRefPubMedGoogle Scholar
- 40.Gimpelewicz C, Metra M, Cleland JGF, Szecsödy P, Chang Wun CC, Boer-Martins L, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang P, Ponikowski P, Severin T, Voors AA, Teerlink JR (2017) Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: a subgroup analysis from the RELAX-AHF trial. Am Heart J. 190:13–122. https://doi.org/10.1016/j.ahj.2017.05.012 CrossRefPubMedGoogle Scholar
- 45.O’Connor CM, Abraham WT, Albert NM et al (2008) Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 156:662–673CrossRefPubMedGoogle Scholar
- 46.Cleland JG, Chiswell K, Teerlink JR et al (2014) Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Circ Heart Fail 7:76–87CrossRefPubMedGoogle Scholar
- 50.Pang PS (2017) B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial (BLUSHED-AHF). http://www.clinicaltrial.gov (NCT03136198)